Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medro vs ReadyRx

Medro
Graded #255

Lower grade

vs+3.999999999999993
ReadyRx
Graded #168

Higher grade

The verdict

ReadyRx takes it — 67.6/100 to 63.6/100.

ReadyRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ReadyRx (readyrx.com) is a LegitScript-certified US telehealth provider offering compounded semaglutide from $179/mo and compounded tirzepatide from $255/mo, plus NAD+, sermorelin, glutathione, MIC+B12, and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueReadyRx +10
50
60
Dose & formulationMedro +13
77
64
Clinical oversightReadyRx +8
71
79
Labs & monitoringReadyRx +12
52
64
FulfillmentMedro +9
92
83
Contract termsReadyRx +22
33
55
Medro · left barReadyRx · right bar

The numbers

MetricMedroReadyRx
WeighScore63.6/10067.6/100
GradeCC
Scorecard rank#255#168
Semaglutide$199/mo (compounded)$179/mo (starting dose, compounded)
Tirzepatide$299/mo (compounded)$255/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.
ReadyRx

Graded #168 · C

Strengths

  • LegitScript Certified — verifiable via the badge link in the footer
  • Batch lab testing covers the right QA metrics for injectables: potency, sterility, pH, and endotoxicity
  • Pricing shown publicly: $179/mo semaglutide, $255/mo tirzepatide

Where it loses points

  • Pharmacy partners not named — only described as 'FDA-registered compounding pharmacies'
  • Clinicians described as licensed and board-certified, but no names or credentials published
  • 5,000+ member figure comes from a directory listing, not an independent audit

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard